Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.
Antigen Presentation
Antigens, Viral
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
Cell Line
Epitopes, T-Lymphocyte
/ immunology
HEK293 Cells
Histocompatibility Antigens Class I
/ immunology
Histocompatibility Antigens Class II
/ immunology
Humans
Peptides
/ immunology
Peptidomimetics
SARS-CoV-2
/ genetics
T-Lymphocytes
HLA
Peptides
Peptidomics
SARS-CoV-2
immuno-reactive
out-of-frame-ORFs
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
29 06 2021
29 06 2021
Historique:
received:
03
11
2020
revised:
17
01
2021
accepted:
03
06
2021
pubmed:
25
6
2021
medline:
13
7
2021
entrez:
24
6
2021
Statut:
ppublish
Résumé
The human leukocyte antigen (HLA)-bound viral antigens serve as an immunological signature that can be selectively recognized by T cells. As viruses evolve by acquiring mutations, it is essential to identify a range of presented viral antigens. Using HLA peptidomics, we are able to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides presented by highly prevalent HLA class I (HLA-I) molecules by using infected cells as well as overexpression of SARS-CoV-2 genes. We find 26 HLA-I peptides and 36 HLA class II (HLA-II) peptides. Among the identified peptides, some are shared between different cells and some are derived from out-of-frame open reading frames (ORFs). Seven of these peptides were previously shown to be immunogenic, and we identify two additional immunoreactive peptides by using HLA multimer staining. These results may aid the development of the next generation of SARS-CoV-2 vaccines based on presented viral-specific antigens that span several of the viral genes.
Identifiants
pubmed: 34166618
pii: S2211-1247(21)00681-1
doi: 10.1016/j.celrep.2021.109305
pmc: PMC8185308
pii:
doi:
Substances chimiques
Antigens, Viral
0
COVID-19 Vaccines
0
Epitopes, T-Lymphocyte
0
Histocompatibility Antigens Class I
0
Histocompatibility Antigens Class II
0
Peptides
0
Peptidomimetics
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109305Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007290
Pays : United States
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests Patent applications have been filed on SARS-CoV-2 peptides (Y.S., A.N., and S.K.). The remaining authors declare no competing interests.
Références
Nat Protoc. 2006;1(3):1120-32
pubmed: 17406393
Immunity. 2019 Oct 15;51(4):766-779.e17
pubmed: 31495665
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Inform Med Unlocked. 2020;19:100338
pubmed: 32352026
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Immunity. 2017 Feb 21;46(2):315-326
pubmed: 28228285
Signal Transduct Target Ther. 2020 Aug 14;5(1):156
pubmed: 32796814
Nucleic Acids Res. 2017 Jul 3;45(W1):W458-W463
pubmed: 28407089
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Immunity. 2018 Oct 16;49(4):695-708.e4
pubmed: 30291027
Immunogenetics. 2009 Jan;61(1):1-13
pubmed: 19002680
J Virol. 2020 Jun 16;94(13):
pubmed: 32303592
J Hum Genet. 2020 Jul;65(7):569-575
pubmed: 32372051
Nat Methods. 2009 Jul;6(7):520-6
pubmed: 19543285
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Bioinformatics. 2013 Jan 1;29(1):8-14
pubmed: 23097419
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Transl Med. 2021 Apr 21;13(590):
pubmed: 33723016
Genome Med. 2020 Dec 1;12(1):108
pubmed: 33256807
Bioinformatics. 2012 Jan 15;28(2):288-9
pubmed: 22113085
Vet Microbiol. 2020 May;244:108693
pubmed: 32402329
Nature. 2021 Jun;594(7862):240-245
pubmed: 33979833
J Immunol. 2018 Dec 15;201(12):3705-3716
pubmed: 30429286
Vaccine. 2009 Jun 12;27(29):3912-20
pubmed: 19490987
Cell. 2011 Nov 11;147(4):789-802
pubmed: 22056041
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
J Immunol. 1999 Jun 15;162(12):7171-80
pubmed: 10358163
Science. 2009 Apr 10;324(5924):218-23
pubmed: 19213877
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Genome Med. 2020 Aug 13;12(1):70
pubmed: 32791978
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Nat Biotechnol. 2020 Feb;38(2):199-209
pubmed: 31844290
Biochem Biophys Res Commun. 2006 May 26;344(1):63-71
pubmed: 16630549
Science. 2020 Mar 6;367(6482):1140-1146
pubmed: 32139545
J Virol. 2003 Oct;77(19):10179-85
pubmed: 12970403
Nature. 2021 Feb;590(7844):E26
pubmed: 33469216
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Cell Rep. 2014 Sep 11;8(5):1365-79
pubmed: 25159147
Immunity. 2020 Nov 17;53(5):1078-1094.e7
pubmed: 33010224
Nature. 2021 Jan;589(7840):125-130
pubmed: 32906143
J Virol. 2008 Mar;82(6):3147-53
pubmed: 18184704
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Elife. 2021 Jan 05;10:
pubmed: 33399535
Vaccine. 2007 Aug 10;25(32):6070-7
pubmed: 17629360
Cell. 2020 Jun 25;181(7):1475-1488.e12
pubmed: 32479746
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Nat Biotechnol. 2022 Feb;40(2):209-217
pubmed: 34663921
Oncotarget. 2016 Feb 2;7(5):5110-7
pubmed: 26819371
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Nat Protoc. 2019 Mar;14(3):703-721
pubmed: 30804569
Cancer Discov. 2018 Nov;8(11):1366-1375
pubmed: 30209080
J Virol. 2009 Jul;83(13):6664-72
pubmed: 19369343
Elife. 2020 Jan 16;9:
pubmed: 31944176
Nat Biotechnol. 2021 Jun;39(6):697-704
pubmed: 33510483
Science. 2012 Nov 23;338(6110):1088-93
pubmed: 23180859
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
J Clin Invest. 2020 Dec 1;130(12):6631-6638
pubmed: 32966269
Cell. 1993 Nov 19;75(4):693-708
pubmed: 7694806
Nat Rev Mol Cell Biol. 2001 Mar;2(3):179-87
pubmed: 11265247
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Immunol Rev. 2016 Jul;272(1):8-16
pubmed: 27319338
PLoS Comput Biol. 2017 Aug 23;13(8):e1005725
pubmed: 28832583
Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3112-3117
pubmed: 30718433
Virus Res. 2020 Oct 15;288:198082
pubmed: 32621841
Mol Cell Proteomics. 2004 Sep;3(9):908-19
pubmed: 15238601
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Cancer Res. 2003 Feb 1;63(3):636-41
pubmed: 12566307
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Genome Med. 2016 Mar 30;8(1):33
pubmed: 27029192
Nature. 2021 Apr;592(7852):138-143
pubmed: 33731925
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W281-7
pubmed: 22638583
Tissue Antigens. 2004 May;63(5):395-400
pubmed: 15104671
J Virol. 2002 Mar;76(6):3007-14
pubmed: 11861866
Nat Commun. 2020 Dec 16;11(1):6402
pubmed: 33328475
Nat Commun. 2020 Mar 10;11(1):1293
pubmed: 32157095